NJ Drug Co. Dodges Class Action Over FDA Approval Claims

Law360, Newark (May 19, 2017, 9:29 PM EDT) -- A New Jersey federal judge on Friday tossed a proposed securities class action against Eagle Pharmaceuticals Inc., saying investors have failed to back up their claims that the company made false and misleading statements about the nature of a blood thinner and the chances of the drug receiving federal approval.

U.S. District Judge Jose L. Linares granted a dismissal motion from the company and Scott Tarriff, its president and CEO, finding in part that their statements about the likelihood of securing U.S. Food and Drug Administration...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.